Top Markets
#1 Provenance Blockchain Provenance Blockchain +8.22%
#2 ALEO ALEO +7.58%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +5.99%
#4 B3 (Base) B3 (Base) +4.86%
#5 TDCCP TDCCP +4.33%
#6 Cortex Cortex +4.27%
#7 Synapse Synapse +4.24%
#8 Steem Steem +3.89%
#9 MANTRA MANTRA +3.47%
#10 Moo Deng Moo Deng +3.47%
Coin of the day
Provenance Blockchain Provenance Blockchain
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
Rang in Aktien #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
Aktienkurs
$0.04443294
Marktkapitalisierung
$13.65M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-32.53%
Land
AU
Handel Noxopharm Limited (NOX)

Kategorie

Healthcare
Umsatz von Noxopharm Limited (NOX)
Umsatz im Jun 2026 TTM: 0.00
Laut den aktuellen Finanzberichten von Noxopharm Limited beträgt der derzeitige Umsatz des Unternehmens (TTM) 0.00. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $1.60M ein Rückgang im Vergleich zu dem Umsatz im Jahr 2023, der $4.00M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Noxopharm Limited von 2016 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
2026 (TTM) 0.00 -100.00%
2025 $1.86M 15.87%
2024 $1.60M -59.98%
2023 $4.00M 6.95%
2022 $3.74M -10.96%
2021 $4.21M -26.42%
2020 $5.71M 116.95%
2019 $2.63M 288.04%
2018 $678.81K 597.95%
2017 $97.26K 0.00%
2016 0.00 0.00%
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH